고영일 각자 대표는 창업자이며 신약개발에 필요한 연구개발을 총괄하고 있습니다.
서울대학교 병원 혈액종양내과 교수이며 다양한 연구자 또는 회사와의 공동연구 역시 활발히 진행하고 있습니다.
EDUCATION
- PhD., Molecular and Clinical Oncology, Seoul National University, Korea
- Medical Doctor, Seoul National University College of Medicine, Korea
KEY PUBLICATION
- 30+ publications (Blood Cancer Journal, Hematologica, Nature Communications, etc.)
CLINICAL TRIAL EXPERIENCE :
Conducted 40+ clinical trials
- An open–label, multicenter, phase1 trial valuating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma
- A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
- A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies
- A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients with Peripheral T Cell Lymphoma (PTCL)
